Related Experiment Video
Updated: Oct 25, 2025
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
[Performing integrative transcriptomic and chemical screening to identify patient-specific vulnerabilities in
Mari Hashimoto1, Fumihiko Ishikawa1
1RIKEN, Center for Integrative Medical Sciences.
Abstract:
Genetic complexity and heterogeneity have made drug discovery difficult in human malignancies. In the past few years, we aimed to find vulnerabilities in therapy-resistant and refractory acute myeloid leukemia (AML) through integrative analyses of genomic data, clinical information, and results from in vivo/in vitro cell biological assays. Through analyses, we found that the cells of patients with AML show distinct sensitivity/resistance to small inhibiting molecules for anti-apoptosis and cell cycle/division. In particular, AML cells harboring the IDH1/2 mutations were highly sensitive to BCL-2 inhibition, while inhibition of IAP proteins resulted in efficient elimination of AML cells with varied FLT3, NRAS, and CBL mutations. Linking AML-initiating events with appropriate therapeutic strategies through cellular and genomic analyses might be further translated into nonmyeloid malignancies and solid tumors in the future.
Insights
Researchers identified new drug vulnerabilities in acute myeloid leukemia (AML). Targeting BCL-2 or IAP proteins shows promise for therapy-resistant AML, offering hope for future cancer treatments.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Genetic complexity and heterogeneity in human malignancies present significant challenges for drug discovery.
- Therapy-resistant and refractory acute myeloid leukemia (AML) requires novel therapeutic strategies.
Purpose of the Study:
- To identify therapeutic vulnerabilities in therapy-resistant AML through integrative analyses.
- To correlate genomic alterations with drug sensitivity in AML.
Main Methods:
- Integrative analysis of genomic data, clinical information, and in vivo/in vitro cell biological assays.
- Assessment of AML cell sensitivity and resistance to small inhibiting molecules targeting anti-apoptosis and cell cycle pathways.
Main Results:
- AML cells exhibit distinct sensitivities to targeted inhibitors.
- Patients with IDH1/2 mutations showed high sensitivity to BCL-2 inhibition.
- Inhibition of IAP proteins effectively eliminated AML cells with various FLT3, NRAS, and CBL mutations.
Conclusions:
- Linking AML-initiating events with targeted therapies via cellular and genomic analysis is crucial.
- These findings may guide future therapeutic strategies for nonmyeloid malignancies and solid tumors.
